[HTML][HTML] Navigating the “No Man's Land” of TKI-Failed EGFR-mutated non–small cell lung cancer (NSCLC): A review
B Oronsky, P Ma, TR Reid, P Cabrales, M Lybeck… - Neoplasia, 2018 - Elsevier
As the leading cause of cancer-related mortality, lung cancer is a worldwide health issue
that is overwhelmingly caused by smoking. However, a substantial minority (~ 25%) of …
that is overwhelmingly caused by smoking. However, a substantial minority (~ 25%) of …
Emerging drugs for EGFR-mutated non-small cell lung cancer
V Sukrithan, L Deng, A Barbaro… - Expert Opinion on …, 2019 - Taylor & Francis
Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
represent the standard of care for patients with metastatic non-small-cell lung cancer …
represent the standard of care for patients with metastatic non-small-cell lung cancer …
Advanced non-small cell lung cancer with activating epidermal growth factor receptor mutation: first line treatment and beyond
D Rocco, C Battiloro, LD Gravara… - Reviews on Recent …, 2019 - ingentaconnect.com
Background: Lung cancer is the leading cause of cancer mortality, being responsible for
more than 1.6 million deaths each year worldwide and non-small-cell lung cancer (NSCLC) …
more than 1.6 million deaths each year worldwide and non-small-cell lung cancer (NSCLC) …
Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms
C Proto, GL Russo, G Corrao, M Ganzinelli… - Tumori …, 2017 - journals.sagepub.com
In non-small cell lung cancer (NSCLC), the identification of epidermal growth factor receptor
(EGFR) mutations and the parallel development of EGFR tyrosine kinase inhibitors (TKIs) …
(EGFR) mutations and the parallel development of EGFR tyrosine kinase inhibitors (TKIs) …
[HTML][HTML] Resistance to TKIs in EGFR-mutated non-small cell lung cancer: from mechanisms to new therapeutic strategies
Simple Summary Resistance to tyrosine kinase inhibitors (TKIs) of the epidermal growth
factor receptor (EGFR) in advanced mutant non-small cell lung cancer (NSCLC) constitutes …
factor receptor (EGFR) in advanced mutant non-small cell lung cancer (NSCLC) constitutes …
EGFR as a pharmacological target in EGFR-mutant non-small-cell lung cancer: where do we stand now?
YL Wu - Trends in Pharmacological Sciences, 2016 - cell.com
Targeting the epidermal growth factor receptor (EGFR) using tyrosine kinase inhibitors
(TKIs) is highly effective in terms of tumor response rate, survival, and quality of life …
(TKIs) is highly effective in terms of tumor response rate, survival, and quality of life …
[HTML][HTML] Hype or hope–Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant …
F Papini, J Sundaresan, A Leonetti, M Tiseo… - Critical Reviews in …, 2021 - Elsevier
Three generations of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-
TKIs) have been developed for treating advanced/metastatic non-small cell lung cancer …
TKIs) have been developed for treating advanced/metastatic non-small cell lung cancer …
Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC
Opinion statement Patients whose tumors harbor somatic-activating mutations within the
epidermal growth factor receptor (EGFR) gene define a clinically distinct molecular cohort of …
epidermal growth factor receptor (EGFR) gene define a clinically distinct molecular cohort of …
[HTML][HTML] Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management
Non-small-cell lung cancer (NSCLC) constitutes 85% of patients diagnosed with lung
cancer. In metastatic cases, its treatment classically consists of systemic cytotoxic …
cancer. In metastatic cases, its treatment classically consists of systemic cytotoxic …
[HTML][HTML] Strategies to improve outcomes of patients with EGFR-mutant non–small cell lung cancer: review of the literature
C Zhou, L Di Yao - Journal of Thoracic Oncology, 2016 - Elsevier
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) monotherapy has
been regarded as the standard first-line treatment of advanced non–small cell lung cancer …
been regarded as the standard first-line treatment of advanced non–small cell lung cancer …